Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.77 USD | -0.17% | -6.13% | +66.35% |
05-13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
05-13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.35% | 2.69B | |
+4.67% | 111B | |
+11.01% | 105B | |
-12.31% | 22.34B | |
-3.90% | 21.93B | |
-6.08% | 18.59B | |
-36.52% | 18.12B | |
-9.92% | 16.96B | |
+2.80% | 13.7B | |
+36.06% | 12.45B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- BMO Capital Adjusts Price Target on Merus to $47 From $46, Maintains Outperform Rating